Overview

Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin

Status:
RECRUITING

Trial end date:
2024-07-14

Target enrollment:

Participant gender:

Summary

Investigate the efficacy and safety of HSK16149 capsule in Chinese patients with Diabetic Peripheral Neuropathic Pain (DPNP) who had an inadequate response to Pregabalin, following 4 weeks treatment in comparison to Pregabalin

Phase:

PHASE2

Details

Lead Sponsor:

Haisco Pharmaceutical Group Co., Ltd.

Treatments:

BID protein, human
Pregabalin